JP2012530086A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530086A5
JP2012530086A5 JP2012515356A JP2012515356A JP2012530086A5 JP 2012530086 A5 JP2012530086 A5 JP 2012530086A5 JP 2012515356 A JP2012515356 A JP 2012515356A JP 2012515356 A JP2012515356 A JP 2012515356A JP 2012530086 A5 JP2012530086 A5 JP 2012530086A5
Authority
JP
Japan
Prior art keywords
disorder
dementia
disease
group
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012515356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530086A (ja
JP5768044B2 (ja
Filing date
Publication date
Priority claimed from PCT/DK2009/050134 external-priority patent/WO2009152825A1/en
Application filed filed Critical
Priority claimed from PCT/DK2010/050147 external-priority patent/WO2010145668A1/en
Publication of JP2012530086A publication Critical patent/JP2012530086A/ja
Publication of JP2012530086A5 publication Critical patent/JP2012530086A5/ja
Application granted granted Critical
Publication of JP5768044B2 publication Critical patent/JP5768044B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012515356A 2009-06-19 2010-06-17 Ｐｄｅ１０ａ酵素阻害剤としての新規のフェニルイミダゾール誘導体 Expired - Fee Related JP5768044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPCT/DK2009/050134 2009-06-19
PCT/DK2009/050134 WO2009152825A1 (en) 2008-06-20 2009-06-19 Novel phenylimidazole derivatives as pde10a enzyme inhibitors
PCT/DK2010/050147 WO2010145668A1 (en) 2009-06-19 2010-06-17 Novel phenylimidazole derivative as pde10a enzyme inhibitor

Publications (3)

Publication Number Publication Date
JP2012530086A JP2012530086A (ja) 2012-11-29
JP2012530086A5 true JP2012530086A5 (el) 2015-01-29
JP5768044B2 JP5768044B2 (ja) 2015-08-26

Family

ID=42321053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012515356A Expired - Fee Related JP5768044B2 (ja) 2009-06-19 2010-06-17 Ｐｄｅ１０ａ酵素阻害剤としての新規のフェニルイミダゾール誘導体

Country Status (27)

Country Link
EP (1) EP2443105B1 (el)
JP (1) JP5768044B2 (el)
AR (1) AR077144A1 (el)
AU (1) AU2010262190B2 (el)
CA (1) CA2765750A1 (el)
CR (1) CR20110654A (el)
CY (1) CY1115971T1 (el)
DK (1) DK2443105T3 (el)
DO (1) DOP2011000397A (el)
ES (1) ES2527216T3 (el)
GE (1) GEP20146100B (el)
GT (1) GT201100322A (el)
HR (1) HRP20141222T1 (el)
IL (1) IL216684A (el)
MA (1) MA33367B1 (el)
MX (1) MX2011013400A (el)
MY (1) MY156785A (el)
NZ (1) NZ597203A (el)
PL (1) PL2443105T3 (el)
PT (1) PT2443105E (el)
SG (1) SG176680A1 (el)
SI (1) SI2443105T1 (el)
SM (1) SMT201500003B (el)
TW (1) TW201100430A (el)
UA (2) UA102693C2 (el)
WO (1) WO2010145668A1 (el)
ZA (1) ZA201109271B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
US8552045B2 (en) 2010-11-19 2013-10-08 H. Lundbeck A/S Tricyclic imidazole compounds as PDE10 inhibitors
JO3089B1 (ar) * 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
WO2013034761A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Pyridine compounds and uses thereof
WO2013034758A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Substituted triazolopyrazines and uses thereof
WO2013034755A1 (en) * 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
CN103874701A (zh) * 2011-09-09 2014-06-18 H.隆德贝克有限公司 吡啶化合物和其用途
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013107856A1 (en) * 2012-01-20 2013-07-25 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2020094590A1 (en) * 2018-11-06 2020-05-14 H. Lundbeck A/S 5,8-dimethyl-2-[2-(1-methyl-4-phenyl-1h-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate
BR112020013697A2 (pt) * 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826833A (en) 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
FR2824065A1 (fr) 2001-04-26 2002-10-31 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
EP1541564A1 (en) 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
US20060128695A1 (en) 2002-10-30 2006-06-15 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
CA2530114A1 (en) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors
UA86591C2 (ru) 2003-06-30 2009-05-12 Алтана Фарма Аг Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
WO2005082883A2 (en) 2004-02-18 2005-09-09 Pfizer Products Inc. Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US20070265256A1 (en) * 2006-02-21 2007-11-15 Arrington Mark P Phosphodiesterase 10 inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Similar Documents

Publication Publication Date Title
JP2012530086A5 (el)
US20220370442A1 (en) Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof
HRP20141222T1 (hr) Novi derivati fenilimidazola kao inhibitori enzima pde10a
Ding et al. Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro
Jellinger et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease
Ruganzu et al. TREM2 overexpression rescues cognitive deficits in APP/PS1 transgenic mice by reducing neuroinflammation via the JAK/STAT/SOCS signaling pathway
Adwan et al. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease
Tsilioni et al. Exosomes in neurologic and psychiatric disorders
RU2014101482A (ru) Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении
JP2023159345A (ja) 新規組成物および方法
WO2012036433A3 (ko) miRNA를 타겟으로 한 신경퇴행성 질환 치료
CO6362014A2 (es) Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso
EA200901373A1 (ru) Аминогетероциклические соединения
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
JP2017525721A (ja) 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
JP7319369B2 (ja) ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
Yu et al. Epigenetic modulation on tau phosphorylation in Alzheimer’s disease
RU2007135202A (ru) Лечение пациентов, страдающих психическими заболеваниями, с печеночной недостаточностью палиперидоном
JP2023181398A (ja) 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
Ono et al. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature
CL2007002768A1 (es) Compuestos derivados de quinolin-amina; proceso de preparacion de dichos compuestos; medicamento; y uso para el tratamiento de enfermedades tales como depresion, trastornos de ansiedad, esquizofrenia, agorafobia, dolor, demencia y enfermedad de parki
US20240065988A1 (en) Combined use of ketamine and retigabine (ezogabine) for the treatment of psychiatric disorders
RU2009123347A (ru) Соль сукцинат 2-(1-метил-4-(пиридин-4-ил)-1н-пиразол-3-ил)фенокси)метил)хинолина
Shallie et al. Amyloid-beta (1-42) lesion of CA1 rat dorsal hippocampus reduces contextual fear memory and increases expression of microglial genes regulating neuroinflammation
Skokou et al. Active and prodromal phase symptomatology of young-onset and late-onset paranoid schizophrenia